Award supports development of a pre-clinical cell-based assay platform to help scientists discover and test drug candidates for metastatic breast cancer

Xylyx Bio, a regenerative medicine company developing innovative solutions for tissue and organ repair, today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor...

The scarcity of suitable donor livers highlights a continuing need for innovation to recover organs with reversible injuries in liver transplantation.

Improved approaches to expanding the pool of donor lungs suitable for transplantation are critically needed for the growing population with end-stage lung disease.

Xenogeneic cross-circulation (XC) is an experimental method for ex vivo organ support and recovery that could expand the pool of donor lungs suitable for transplantation. The objective of this study was to establish and validate...

Study demonstrates that a novel technique for regenerating donor lungs can increase the number of organs available for life-saving transplantation

Despite increasing use of machine perfusion as an organ preservation and rescue technique in liver transplantation, significant organ shortages and waitlist mortality highlight a continuing need for improved organ recovery methods. 

Manifestations of cystic fibrosis, although well-characterized in the proximal airways, are understudied in the distal lung. Characterization of the cystic fibrosis lung 'matrisome' (matrix proteome) has not been previously described, and could help identify biomarkers...

Researchers at the University of Illinois applied Xylyx Bio's IN SITE™ Metastasis Kit to evaluate a cancer therapeutic.